Please upgrade your browser.
The Kidney Cancer Association’s vice president for public affairs, Carrie Konosky, is in Happy Valley, PA, this weekend to receive funds from the Penn State Chapter of Uplifting Athletes.
Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma
The aims of this study were to quantify and contrast patient preferences between second-line advanced renal cell carcinoma (RCC) medication profiles and their associated benefits and toxicities, and to help frame the doctor-patient discussion about selecting appropriate RCC therapies.
Since the mid-1990s, black Americans have had a higher incidence of renal cell carcinoma, the most common form of kidney cancer, than white Americans. Research also suggests that there are racial disparities in the survival of patients with renal cell carcinoma, with black patients dying earlier than whites.
Hornbuckle, known as the “Soul Diva of the Northwest,” was diagnosed with kidney cancer in August. She's currently undergoing chemotherapy, but keeping a positive attitude.
Regardless of patient and tumor characteristics or surgical treatment, white patients with kidney cancer consistently have a survival advantage over black patients.
The future for kidney cancer patients could be bleak, if this Wall Street Journal op-ed's conclusions are accurate.
There were more than 250 generic drug shortages in 2011 compared with 58 in 2004, thanks largely to the Medicare Modernization Act.
In the Western world the incidence of renal cell carcinoma (RCC) has been increasing for several decades.
The highly conserved WNT pathway is involved in the transduction of signals from the cell surface to the nucleus, and it is known to play a key role in embryonic development, adult tissue maintenance and tumourigenesis (Klaus & Birchmeier, 2008).
We assessed temporal shifts in the frequency of risk factors for patients with metastatic renal cell carcinoma in a multicenter, international data set.
|Powered by NeonCRM|